

APR - 9 2012

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of 21 CFR Part 807.92.

Date: July 3, 2011

1. Company and Correspondent making the submission:

Name – Shine Overseas Marketing Limited

Address – Unit 1, 14/F., Yue Xiu Building, 160-174 Lockhart Road, Wanchai,
Hong Kong, China

Telephone – +86-755-8618 2000

Fax – +86-755-8618 2500

Contact – Jacky Lee

Email – charliemack@irc-us.com

2. Device :

Trade/proprietary name: Shine Overseas Marketing Limited; Weight and Body Fat
Scale, SHINE BS0105

Common Name : Analyzer, Body Fat

Classification Name : Impedance plethysmograph

3. Predicate Devices :

Tanita BC-533, (K040778)

4. Classifications Names & Citations :

21CFR 870.2770, MNW, Body Fat Analyzer, Class 2

5. Description :

5.1 General

The patient steps on the scale device, where two electrodes are located. The patient must step on the electrodes with bare feet, with normal moisture. Through harmless current stimulation of 500 μ A, at 50 kHz, the Shine Overseas Marketing Limited Weight and Body Fat Scale calculates the body fat percentage. This calculation is done via the Bioelectrical Impedance Method. The current is passed through the body and the impedance of the body determines the body fat. The calculation is based upon electrical impedance, height, weight, age, and gender. The calculation is performed via internal software, which uses the variables programmed in by the user. There are elements of this process that can produce erroneous readings, such as dry feet or improper-programmed data. The User's Manual defines items which could cause erroneous readings.

5.2 Direction

As discussed in the General description, the Shine Overseas Marketing Limited Weight and Body Fat Scale is relatively simple to use. The user inputs the variable data of age, height, and gender. The user steps onto the scale and the device measures the user weight and body impedance (via the Bioelectric Impedance through the two electrodes on the scale). The scale displays the user's body fat composition. Upon the user's selection, the device can also display the user's weight.

6. Indication for use :

The Shine Overseas Marketing Limited Weight & Body Fat Monitoring Scale, Model BS0105 is indicated to measure body weight, estimate body fat, body water percentage, body muscle mass and bones mass using BIA (bioelectrical impedance analysis). This product is for use by generally healthy adults (from ages 18 to 80) who are not ill, feverish, have a chronic or acute disease, or a condition that affects the level of hydration such as pregnancy.

7. Comparison with predicate device :

Shine Overseas Marketing Limited believes that the Shine Overseas Marketing Limited Weight and Body Fat Scale is substantially equivalent to the Tanita BC-533 (K040778).

8. Safety and Performance Data :

Electrical, mechanical, environmental safety and performance testing according to standard EN/IEC 60601-1. Clinical testing was used to validate the effectiveness and accuracy of the device. All test results were satisfactory.

9. Conclusions:

In accordance with the Federal Food, Drug and Cosmetic Act, 21 CFR Part 807 and based on the information provided in this premarket notification TH Leaguer. Inc. concludes that The Shine Overseas Marketing Limited Weight and Body Fat Scale is safe and effective and substantially equivalent to predicate devices as described herein.

END



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room - WO66-G609
Silver Spring, MD 20993-0002

SHINE OVERSEAS MARKETING LIMITED
% Mr. Charlie Mack
Principal Engineer
IRC
77325 Joyce Way
ECHO OR 97826

APR -9 2012

Re: K112149
Trade/Device Name: Weight & Body Fat Monitoring Scale, Model BS0105
Regulation Number: 21 CFR§ 870.2770
Regulation Name: Impedance plethysmograph
Regulatory Class: II
Product Code: MNW
Dated: March 26, 2012
Received: April 4, 2012

Dear Mr. Mack:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucml15809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Benjamin R. Fisher, Ph.D.

Director

Division of Reproductive, Gastro-Renal,
and Urological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): _____

Device Name: Weight & Body Fat Monitoring Scale, Model BS0105

Indications for Use:

The Shine Overseas Marketing Limited Weight & Body Fat Monitoring Scale, Model BS0105 is indicated to measure body weight, estimate body fat, body water percentage, body muscle mass and bones mass using BIA (bioelectrical impedance analysis). This product is for use by generally healthy adults (from ages 18-80) who are not ill, feverish, have a chronic or acute disease, or a condition that affects the level of hydration such as pregnancy.


Prescription Use _____
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use X
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)
Division of Reproductive, Gastro-Renal, and
Urological Devices
510(k) Number K 112149

Page ___ of ___